Showing 1391-1400 of 3001 results for "".
- Teens with Epilepsy Are More Likely to Discuss Suicide Onlinehttps://practicalneurology.com/news/teens-with-epilepsy-are-more-likely-to-discuss-suicide-online/2469098/Results of a study presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD show that teens with epilepsy are more than twice as likely as adults with the condition to talk about suicide online. The data suggests that teens are concerned with the unknown aspe
- Women with Epilepsy Are Less Likely to Breastfeed Their Newbornshttps://practicalneurology.com/news/women-with-epilepsy-are-less-likely-to-breastfeed-their-newborns/2469096/Findings from 2 clinical studies presented at the American Epilepsy Society Annual Meeting, December 6-10 in Baltimore, MD show that women with epilepsy are less likely to breastfeed their newborns than new mothers without epilepsy. Support from neurologists and lactation consultants, however, ca
- Database of Eye-Tracking Movements Could Aid Diagnosis and Treatmenthttps://practicalneurology.com/news/database-of-eye-tracking-movements-could-aid-diagnosis-and-treatment/2468784/Eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) that captures data on people’s eye movements has been used to produce a database of 1 billion data points from 100,000 individuals. Data includes eye tracking measures of alignment, object tracking, depth perception, and dy
- FDA Provides Expanded Clearance for Device to Treat Migraine in Childrenhttps://practicalneurology.com/news/fda-provides-expanded-clearance-for-device-to-treat-migraine-in-children/2468822/The Food and Drug Administration (FDA) has granted new marketing clearance for a device that provides acute and preventive treatment of migraine to include children 12 years of age and older. The technology (sTMS; eNeura, Inc., Baltimore, MD) is a non-invasive device that uses single-puls
- FDA Greenlights Phase 2a Trial of Intranasal Foralumab in Multiple System Atrophyhttps://practicalneurology.com/news/fda-greenlights-phase-2a-trial-of-intranasal-foralumab-in-multiple-system-atrophy/2476103/The Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application, permitting the evaluation of treatment with intranasal foralumab (Tiziana Life Sciences, New York, NY) for people with multiple system atrophy (MSA) in a phase 2a clinical trial (NCT06868628). MSA i
- Cell Therapy for ALS Associated with Increased Survival at 5 Yearshttps://practicalneurology.com/news/cell-therapy-for-als-shows-promise-in-increasing-survival-at-five-years/2475217/Nine out of 10 people with amyotrophic lateral sclerosis (ALS) treated with NurOwn (autologous mesenchymal stem cells [MSC]–neurotrophic factors [NTF]; BrainStorm Cell Therapeutics, New York, NY) survived more than 5 years after symptom onset. These results from an analysis of survival data from
- New Technology May Help Differentiate Between Parkinsonismshttps://practicalneurology.com/news/new-technology-may-help-differentiate-between-parkinsonisms/2473819/A machine learning–based software tool (neuropacs; Gainesville, FL) analyzing 3T diffusion MRI scans was found to be effective in distinguishing between Parkinson disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) in people with diagnosed movement disorder
- Stem Cell Therapy Reduced Brain Atrophy in People with Mild Alzheimer Diseasehttps://practicalneurology.com/news/stem-cell-therapy-reduced-brain-atrophy-in-people-with-mild-alzheimer-disease/2473818/The intravenous (IV) treatment of people with mild Alzheimer disease (AD) using Lomecel-B (laromestrocel; Longeveron, Miami, FL), a bone-marrow–derived allogeneic mesenchymal stem cell (MSC), was associated with reduced atrophy of the whole brain and hippocampus compared with placebo. These
- FDA Grants Fast Track Designation to Potential Treatment for Multiple System Atrophyhttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-potential-treatment-for-multisystem-atrophy/2473790/Amlenetug (Lundbeck, Deerfield, IL), a monoclonal antibody (mAb) that targets extracellular α-synuclein, was granted Fast Track Designation (FTD) by the Food and Drug Administration (FDA) for investigation as a potential treatment for multiple system atrophy (MSA). According to a statement
- Phosphorylated α-Synuclein Detectable by Skin Biopsy in Those with Synucleionopathies Including Parkinson Diseasehttps://practicalneurology.com/news/phosphorylated-a-synuclein-detectable-by-skin-biopsy-in-those-with-synucleionopathies-including-parkinson-disease/2470436/According to study results published in JAMA, a high proportion of people with Parkinson disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and pure autonomic failure (PAF) showed skin biopsies positive for cutaneous phosphorylated α-synuclein. The result